Friday 6 November 2026
Export ISRG’s income statement to Excel — free account
Intuitive Surgical, Inc.
ISRG Healthcare Medical Instruments & Supplies
Intuitive Surgical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.1 billion, up 20.5% from fiscal 2024.
- Revenue
- +21.7%
- EPS
- −24.2%
- Free cash flow
- +51.0%
Quarter to September 2026, against a year earlier
465.68
16.42
−3.41%
Follow ISRG
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
70.71 | 55.08 | 44.99 | 48.64 |
P/S ratio |
20.08 | 15.46 | 12.76 | 12.26 | |
P/FCF ratio |
81.16 | 56.80 | 43.08 | 38.94 | |
P/Operating CF |
226.48 | 179.41 | 132.72 | 115.93 | |
P/B ratio |
11.27 | 9.30 | 7.70 | 8.80 | |
Price to Tangible BV |
12.09 | 10.30 | 8.49 | 9.89 | |
EV/Sales |
19.49 | 15.03 | 12.29 | 11.91 | |
EV/EBITDA |
54.16 | 40.20 | 31.88 | 33.34 | |
EV/Operating CF |
64.74 | 47.34 | 36.59 | 33.71 | |
EV/FCF |
78.77 | 55.23 | 41.49 | 37.84 | |
Quick Ratio |
3.72 | 3.20 | 3.58 | 2.28 | |
Current Ratio |
4.87 | 4.61 | 4.96 | 3.33 | |
Net Debt/EBITDA |
(5.39) | (4.32) | (4.37) | (5.08) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.51 | 0.54 | 0.54 | 0.60 | |
Operating CF/Net income |
1.12 | 1.11 | 1.30 | 2.34 | |
Capex/Depreciation |
(0.69) | (0.30) | (0.51) | (0.55) | |
Research and Development Expense of Revenue |
12.31% | 13.06% | 12.81% | 13.39% | |
Selling, General and Administrative Expense of Revenue |
23.97% | 22.13% | 21.36% | 20.78% | |
Intangible Assets out of Total Assets |
0.06 | 0.08 | 0.08 | 0.09 | |
Share Based Compensation of Revenue |
7.09% | 7.56% | 7.26% | 6.97% | |
Graham Net Nets |
0.04 | 0.04 | 0.05 | 0.04 | |
Graham Number |
95.18 | 96.63 | 101.38 | 93.20 | |
Earnings Yield |
1.41% | 1.82% | 2.22% | 2.06% | |
Free Cash Flow Yield |
1.23% | 1.76% | 2.32% | 2.57% | |
Revenue per Share |
8.03 | 7.81 | 8.17 | 8.74 | |
Operating CF per Share |
2.50 | 2.57 | 3.00 | 3.51 | |
Capex per Share |
(0.46) | (0.16) | (0.32) | (0.32) | |
Free Cash Flow per Share |
2.05 | 2.41 | 2.68 | 3.18 | |
Cash per Share |
16.63 | 12.73 | 14.73 | 11.58 | |
Shareholders Equity per Share |
50.27 | 49.58 | 51.67 | 46.18 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
50.27 | 49.58 | 51.67 | 46.18 | |
Free Cash Flow |
730.00 | 854.60 | 948.40 | 1,111.00 | |
Working Capital |
7,773.30 | 6,898.50 | 7,619.80 | 5,895.30 | |
Capital Expenditures |
(162.50) | (57.30) | (112.60) | (113.10) | |
Net Current Asset Value |
7,262.50 | 6,295.70 | 6,963.80 | 5,197.00 | |
EV/EBIT |
66.61 | 49.36 | 39.29 | 41.98 | |
Capex to Sales |
0.06 | 0.02 | 0.04 | 0.04 | |
Price to Operating Income |
68.62 | 50.77 | 40.80 | 43.21 | |
| Other line items | |||||
Average Receivables |
1,376.35 | 1,408.55 | 1,471.20 | 1,490.50 | |
Average Payables |
224.25 | 304.55 | 272.00 | 285.35 | |
Average Inventory |
1,663.60 | 1,749.35 | 1,847.85 | 1,955.05 | |
Average Assets |
19,600.95 | 19,665.70 | 20,519.90 | 19,350.45 | |
Average Common Equity |
17,235.65 | 17,402.45 | 18,125.40 | 16,579.95 |
Columns are period end dates · fundamentals updated 2 Nov 2026